Current Oncology (Feb 2022)

A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre

  • Parneet K. Cheema,
  • Marco A. J. Iafolla,
  • Massey Nematollahi,
  • FeRevelyn Berco,
  • Deepanjali Kaushik,
  • Priscilla Matthews,
  • William R. Raskin,
  • Kirstin A. Perdrizet,
  • Shaan Dudani,
  • Juhi Husain,
  • Margaret Balcewicz,
  • Philip G. Kuruvilla,
  • Stephen M. Reingold,
  • Henry J. Conter

DOI
https://doi.org/10.3390/curroncol29020074
Journal volume & issue
Vol. 29, no. 2
pp. 869 – 880

Abstract

Read online

The increased use of immune checkpoint inhibitors across cancer programs has created the need for standardized patient assessment, education, monitoring, and management of immune-related adverse events (irAEs). At William Osler Health System in Brampton, Ontario, a practical step-wise approach detailing the implementation of cancer immunotherapy in routine practice was developed. The approach focuses on four key steps: (1) identification of patient educators; (2) development of patient education materials; (3) development of patient monitoring tools; (4) involvement and education of multidisciplinary teams. Here, we provide an in-depth description of what was included in each step and how we integrated the different elements of the program. For each step, resources, tools, and materials that may be useful for patients, healthcare providers, and multidisciplinary teams were developed or modified based on existing materials. At our centre, the program led to improved patient comprehension of irAEs, the ability to act on symptoms (patient self-efficacy), and low rates of emergency room visits at first presentation for irAEs. We recognize that centres may need to tailor the approaches to their institutional policies and encourage centres to adapt and modify the forms and tools according to their needs and requirements.

Keywords